{"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Arm I: Decitabine 0.2mg/kg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"80-89 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}